WHI-P154

Confirm delete?

WHI-P154

Zoom

Cat No: 16178

Biochemicals - Kinase Inhibitors

WHI-P154 is a quinazoline derivative that exhibits immunosuppressive effects by selectively inhibiting JAK3 (IC50 = 1.8 μM versus IC50s > 10 μM for JAK1 and JAK2).{26468} It has been reported to inhibit additional kinases including EGFR (IC50 = 4 nM) ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol

Correlated keywords:

JAKs 3 three janus-associated associated kinases janus JAK3 inhibitors inhibits inhibitions immunosuppression immunosuppressive epidermal growths factors receptors EGFR lymphocyte-speci?c lymphocytes specific proteins Lck tyrosines kinase vascular endothelial receptors VEGFR stems cells differentiation WHI-P 154 WHI P154 P quinazolines derivatives Abl Lck Src cytotoxic cytotoxicity glioblastoma neurons neuronal precursors cancers immunology intracellular signaling signals neurosciences transduction research

Product Overview:
WHI-P154 is a quinazoline derivative that exhibits immunosuppressive effects by selectively inhibiting JAK3 (IC50 = 1.8 μM versus IC50s > 10 μM for JAK1 and JAK2).{26468} It has been reported to inhibit additional kinases including EGFR (IC50 = 4 nM) and VEGFR as well as the non-receptor tyrosine kinases, Abl, Lck, and Src.{26468} WHI-P154 is cytotoxic to human glioblastoma cells (IC50 = 813 nM) and has been used to induce the differentiation of neuronal precursor cells.{26470,26471,26469}

Size	5 mg
Shipping	dry ice
CAS Number	211555-04-3
Molecular Formula	C₁₆H₁₄BrN₃O₃
SMILES	COC1=C(OC)C=C(C(NC2=CC(Br)=C(O)C=C2)=NC=N3)C3=C1
Molecular Weight	376,2
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.